Bionano Genomics vs MaxCyte
MaxCyte reported revenue of $33 million in fiscal 2025, 1.2 times Bionano Genomics' $28 million in fiscal 2025. Bionano Genomics' revenue fell 7.4% in its latest year, and MaxCyte's fell 14.5%. Bionano Genomics had an operating margin of -117.0%, against -157.1% at MaxCyte. Free cash flow was −$16 million at Bionano Genomics and −$36 million at MaxCyte.
Side by side
| Bionano Genomics | MaxCyte | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $28M | $33M |
| Revenue growth | −7.4% | −14.5% |
| Revenue growth a year, last 5 years | 27.4% | 4.7% |
| Gross margin | 46.2% | 81.2% |
| Operating margin | −117.0% | −157.1% |
| Net margin | −92.6% | −135.1% |
| Free cash flow | −$16M | −$36M |
| Free cash flow margin | −57.3% | −109.5% |
| Return on capital | −89.9% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 328.4% | 1.5% |
| Last close | $0.89 | $1.28 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | bought $120,780, sold $8,316 |
| Piotroski F-score | 5 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Bionano GenomicsMaxCyte
Operating margin
Percent of revenue
Bionano GenomicsMaxCyte
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Bionano GenomicsMaxCyte
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Bionano Genomics and MaxCyte pages.